|New Threads Only:|
|New Threads & Replies:|
Forum List » Guru News and Commentaries|
Guru News, Stock picks and commentaries
Insiders Are Buying Idera Pharmaceuticals
Posted by: Markus Aarnio (IP Logged)
Date: September 19, 2013 04:33PM
One biotech company has seen intensive insider buying during the last 30 days. Intensive insider buying can be defined by the following three criteria:
The stock is purchased by three or more insiders within one month.
The stock is sold by no insiders in the month of intensive purchasing.
At least two purchasers increase their holdings by more than 10%.
Idera Pharmaceuticals (IDRA), a clinical stage biotechnology company, engages in the discovery and development of novel synthetic DNA- and RNA-based drug candidates.
Insider Buying During the Last 30 Days
Here is a table of Idera's insider-trading activity by calendar month.
There have been 469,311 shares purchased, and there have been zero shares sold by insiders this year.
Idera reported the second-quarter financial results on Aug. 15 with the following highlights:
With cash and cash equivalents of $16.3 million at the end of the second quarter, Idera believes it has funds to complete its Phase 2 clinical trial of IMO-8400 in patients with psoriasis and to fund its operations through year-end 2014.
Idera has two lead candidates in development for the treatment of autoimmune diseases:
During the second quarter Idera presented clinical proof-of-concept data of TLR antagonism and initiated a Phase 2 trial of its lead TLR antagonist, IMO-8400, in patients with moderate-to-severe plaque psoriasis. Idera expects data from the Phase 2 trial to be available during the first quarter of 2014.
Idera's principal competitor developing TLR-targeted compounds for autoimmune and inflammatory diseases is Dynavax (DVAX), with its collaborator GlaxoSmithKline (GSK). Merck's vaccines using Idera's TLR7, TLR8 or TLR9 agonists as adjuvants may compete with vaccines using TLR agonists as adjuvants being developed or marketed by GlaxoSmithKline, Novartis (NVS), Dynavax, VaxInnate, Intercell AG (INRLF.PK) and Cytos Biotechnology AG (CSBTF.PK).
Idera is also developing drug candidates for the treatment of moderate to severe plaque psoriasis. There are a number of well-known immune suppressors and biologics that are currently being widely used for the treatment of moderate to severe plaque psoriasis, including methotrexate and cyclosporine, which are both immune suppressors, and biologics like Enbrel, which is marketed by Amgen (AMGN), Pfizer (PFE) and Takeda Pharmaceutical Company (TKPHF.PK), Remicade, which is marketed by Janssen Biotech (JNJ), Merck and Mitsubishi Tanabe Pharma (MTZPY.PK), Humira, which is marketed by Abbott Laboratories (ABT), and Stelara, which is marketed by Janssen Biotech.
In addition to existing treatments, Idera is also aware of additional compounds for the treatment of moderate to severe plaque psoriasis that are currently in late stage development, including apremilast, which is being developed by Celgene Corporation (CELG), tofacitinib, which is being developed by Pfizer, secukinumab, which is being developed by Novartis, ixekizumab, which is being developed by Eli Lilly and Company (LLY), and brodalumab, which is being developed by Amgen, AstraZeneca (AZN) and Kyowa Hakko Kirin Co.
There have been three different insiders buying Idera and there have not been any insiders selling Idera during the last 30 days. All three of these insiders increased their holdings by more than 10%. Idera has an insider ownership of 6.60%.
The next catalyst for Idera will be the IMO-8400 Phase 2 trial data anticipated during the first quarter of 2014. Idera is fully funded through year-end 2014. I have a cautiously bullish bias for the stock currently based on the intensive insider buying.
Disclosure: I have no positions in any stocks mentioned.
Stocks Discussed: IDRA, ABT, AMGN, AZN, CELG, CSBTF.PK, DVAX, GSK, INRLF.PK,
Disclaimers: GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.